HCA shares took a notable dip after the hospital chain revealed that the financial burden of treating uninsured patients effectively neutralized its recent revenue gains. The struggle to manage these specific costs cast a shadow over the broader hospital subsector, even as other segments showed signs of resilience.

In contrast, Swiss pharmaceutical giant Novartis saw its stock climb following a robust third-quarter performance. Meanwhile, the insurance market remained volatile; Centene shares reacted to the company raising its growth outlook for the third time this year, fueled by successful efforts to keep medical expenditure in check. British drugmaker GSK is also signaling a shift in momentum, with top researchers indicating plans to double its oncology clinical trials next year, a move intended to capitalize on the firm's recent streak of strategic acquisitions.